NCT06561360 2026-03-18
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
30 trialsNCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05783596 2026-03-16
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07218510 2026-03-13
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT02629809 2026-03-06
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05650723 2026-02-25
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04169737 2026-02-24
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05536349 2026-02-24
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03198026 2026-02-19
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05336812 2026-02-19
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT02846623 2026-02-17
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03410875 2026-02-12
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06558604 2026-02-11
GLOASIS
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT03516617 2026-02-09
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT04560322 2026-02-04
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Phase 2 Recruiting
NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT02427451 2026-01-27
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06333262 2026-01-21
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07355699 2026-01-21
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Phase 4 Recruiting
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT06213311 2026-01-14
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07326371 2026-01-08
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT04843904 2026-01-07
SAVE
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06043674 2026-01-07
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04505254 2025-12-26
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05929222 2025-12-24
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT07299149 2025-12-23
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting